Skip to main content

Back

References

May 2023, International Journal of Biological Macromolecules

Molecular insights into the inhibition of early stages of Aβ peptide aggregation and destabilization of Alzheimer’s Aβ protofibril by dipeptide D-Trp-Aib: A molecular modelling approach
(D-Trp-Aib refers to the same compound as GAL-101)

May 2022, International Journal of Molecular Science

The Small Molecule GAL-201 Efficiently Detoxifies Soluble Amyloid β Oligomers: New Approach towards Oral Disease-Modifying Treatment of Alzheimer’s Disease.

August 2021, Journal of Glaucoma

Visual Field Endpoints Based on Subgroups of Points May Be Useful in Glaucoma Clinical Trials: A Study With the Humphrey Field Analyzer and Compass Perimeter

February 2021, Scientific Reports

Improved sensitivity of microperimetric outcomes for clinical studies in age-related macular degeneration

November 2020, Neuropharmacology

The Aβ aggregation modulator MRZ-99030 prevents and even reverses synaptotoxic effects of Aβ1-42 on LTP even following serial dilution to a 500:1 stoichiometric excess of Aβ1-42, suggesting a beneficial prion-like seeding mechanism.

May 2015, Neuropharmacology

MRZ-99030 – A novel modulator of Aβ aggregation: II – Reversal of Aβ oligomer-induced deficits in long-term potentiation (LTP) and cognitive performance in rats and mice

May 2015, Neuropharmacology

MRZ-99030 – A novel modulator of Aβ aggregation: I – Mechanism of action (MoA) underlying the potential neuroprotective treatment of Alzheimer’s disease, glaucoma and age-related macular degeneration (AMD).

August 2014, Neurotoxicity Research

Effect of the Aβ aggregation modulator MRZ-99030 on retinal damage in an animal model of glaucoma.

February 2009, Angewandte Chemie (International ed. in English)

Cognitive-performance recovery of Alzheimer’s disease model mice by modulation of early soluble amyloidal assemblies
(D-Trp-Aib refers to the same compound as GAL-101)